What Natera’s Signatera CDx approval changes for adjuvant Tecentriq use in bladder cancer
MRD testing just crossed into treatment selection. Natera’s Signatera FDA win could reshape adjuvant bladder cancer care.
Genentech’s Tecentriq decision puts Natera’s Signatera at the centre of precision bladder cancer care
Bladder cancer treatment is becoming more selective. Tecentriq’s ctDNA-guided approval may redefine who gets adjuvant immunotherapy.
Can ctDNA-guided bladder preservation become viable after Signatera’s ASCO GU data?
New ASCO GU data shows how Signatera ctDNA may guide bladder preservation and adjuvant therapy decisions in muscle-invasive bladder cancer. Read the analysis.
Can personalized ctDNA finally solve the risk stratification gap in therapy-resistant early breast cancer?
New I-SPY 2 data suggest personalized ctDNA could transform risk stratification in therapy-resistant early breast cancer. Read the full analysis.
Why the MiRaDoR study may redefine therapeutic timing in HR+/HER2- patients
Natera Inc. and Medica Scientia Innovation Research (MEDSIR) have announced a collaborative effort on the MiRaDoR study, a multicenter, phase II clinical trial focused on hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer. Sponsored by MEDSIR and funded by F. Hoffmann-La Roche Ltd., the trial uses Natera’s Signatera assay to guide therapy decisions based on circulating tumor […]